Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug 5;8(8):e0509.
doi: 10.1097/HC9.0000000000000509. eCollection 2024 Aug 1.

ICIs in hepatocellular carcinoma: A comprehensive analysis of path forward for multimodal treatment strategies

Shixuan Peng  1   2   3 , Qisheng Chen  4 , Yongjun Wu  2   3
Affiliations
Editorial

ICIs in hepatocellular carcinoma: A comprehensive analysis of path forward for multimodal treatment strategies

Shixuan Peng et al. Hepatol Commun. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts to report.

Comment on

  • Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
    Celsa C, Cabibbo G, Fulgenzi CAM, Scheiner B, D'Alessio A, Manfredi GF, Nishida N, Ang C, Marron TU, Saeed A, Wietharn B, Pinter M, Cheon J, Huang YH, Lee PC, Phen S, Gampa A, Pillai A, Vivaldi C, Salani F, Masi G, Roehlen N, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, El Tomb P, Ulahannan S, Parisi A, Chon HJ, Hsu WF, Stefanini B, Verzoni E, Giusti R, Veccia A, Catino A, Aprile G, Guglielmini PF, Di Napoli M, Ermacora P, Antonuzzo L, Rossi E, Verderame F, Zustovich F, Ficorella C, Di Pietro FR, Battelli N, Negrini G, Grossi F, Bordonaro R, Pipitone S, Banzi M, Ricciardi S, Laera L, Russo A, De Giorgi U, Cavanna L, Sorarù M, Montesarchio V, Bordi P, Brunetti L, Pinto C, Bersanelli M, Cammà C, Cortellini A, Pinato DJ. Celsa C, et al. J Hepatol. 2024 Mar;80(3):431-442. doi: 10.1016/j.jhep.2023.10.040. Epub 2023 Nov 15. J Hepatol. 2024. PMID: 37972660

References

    1. Celsa C, Cabibbo G, Fulgenzi CAM, et al. . Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. J Hepatol. 2024;80:431–42. - PubMed
    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49. - PubMed
    1. Vogel A, Meyer T, Sapisochin G, et al. . Hepatocellular carcinoma. Lancet. 2022;400:1345–62. - PubMed
    1. Pinato DJ, Fulgenzi CAM, D’Alessio A. Immunotherapy at all stages of hepatocellular carcinoma. Nat Med. 2024;30:640–1. - PubMed
    1. Zheng C, Huang S, Lin M, et al. . Hepatotoxicity of immune checkpoint in hibitors: What is currently known. Hepatol Commun. 2023;7:e0063. - PMC - PubMed

MeSH terms

Substances